Roche targets new central nervous system drugs

pharmafile | January 5, 2007 | News story | Research and Development  

Swiss-based Roche has forged a partnership that could lead to the development of new treatments for schizophrenia, cognitive disorders, Parkinson's disease, drug dependency and pain.

It has teamed up with biotech company Synosis, which will acquire five drug candidates from Roche, to target diseases of the central nervous system.

US company Synosis  which has offices in Basle, Switzerland – will be responsible for developing these drug compounds and in some cases, marketing them in multiple indications. Roche will retain the right to opt in to two pre-selected drug programmes.

Financial terms of the deal were not disclosed.

Peter Hug, Roche's global head of pharma partnering, said:"By partnering with Synosis, we are giving these potential medicines the best chance of success by creatively extending our innovation base in an important therapeutic area."

He added: "There is a real need for new treatments for central nervous system diseases, such as schizophrenia and Parkinson's and we are delighted by the potential of this partnership."

Sales by Roche's pharmaceutical division totalled 27.3 billion Swiss francs in 2005 and its diagnostics division posted sales of 8.2 billion francs in the same year.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Related Content

No items found

Latest content